Tony W. Ng, PhD

Research Associate
Department of Microbiology & Immunology
Albert Einstein College of Medicine
1300 Morris Park Avenue
Forchheimer Building, Rm 416
Bronx, NY 10461, USA



Dr. Ng earned his PhD in Molecular Genetics and Microbiology from Stony Brook University in New York. He started his postdoctoral training with the NIH/NIAID Rocky Mountain Laboratories in Montana by studying the intracellular trafficking of Brucella abortus. To extend his postdoctoral training in the field of immunology and vaccine development, he joined the Department of Microbiology & Immunology in Albert Einstein College of Medicine located in New York and began working with Mycobacteria. After his postdoctoral trainings, he became a Research Associate at Einstein College of Medicine and continued his work on developing vaccines against tuberculosis.

Research Interest

Dr. Ng focuses in developing vaccines against tuberculosis: Develop attenuated forms of M. bovis BCG and M. tuberculosis to improve safety and immunogenicity as vaccines against tuberculosis, Express HIV antigens in attenuated Mycobacteria strains to target both HIV and M. tuberculosis, Enhance Mycobacteria vaccines using glycolipid adjuvants to activate NKT cells and Understand the effect of the immunodominant antigen Ag85B in M. bovis BCG during immunization.

Scientific Activities


• In Proceeding of: 11th Vaccines Research & Development All Things Considered Invited Oral Presentation (2013)
• American Society for Microbiology Student Travel Grant Award (2005)
• St Jude National Graduate Student Symposium Invited Participant (2004)
• Stony Brook University Molecular Genetics and Microbiology Retreat Best Poster Award (2003)


1. Ng TW, Saavedra-Ávila NA, Kennedy SC, Carreno LJ, Porcelli SA. Current efforts and future prospects in the development of live mycobacteria as vaccines. Expert Rev Vaccines. 2015; 14: 1-15.
2. Arora P, Kharkwal SS, Ng TW, et al. Endocytic pH regulates cell surface localization of glycolipid antigen loaded CD1d complexes. Chem Phys Lipids. 2015; 191: 75-83. doi: 10.1016/j.chemphyslip.2015.08.010
3. Hart BE, Asrican R, Lim SY, et al. Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors. Clin Vaccine Immunol. 2015; 22(7): 726-741. doi: 10.1128/CVI.00075-15
4. Venkataswamy MM, Ng TW, Kharkwal SS, et al. Improving Mycobacterium bovis BCG as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells. PLoS ONE. 2014; 9(9): e108383. doi: 10.1371/journal.pone.0108383
5. Singh M, Quispe-Tintaya W, Chandra D, et al. Direct incorporation of the NKT-cell activator a-galactosylceramide into a recombinant Listeria monocytogenes improves breast cancer vaccine efficacy. British Journal of Cancer. 2014; 111: 1945-1954. doi: 10.1038/bjc.2014.486.
6. Myeni S, Child R, Ng TW, et al. Brucella modulates secretory trafficking via multiple type IV secretion effector proteins. PLoS Pathog. 2013; 9(8): e1003556. doi: 10.1371/journal.ppat.1003556
7. Henderson NS, Ng TW, Talukder I, Thanassi DG. Function of the usher N-terminus in catalyzing pilus assembly. Mol. Microbiol. 2011; 79: 954-967. doi: 10.1111/j.1365-2958.2010.07505.x
8. Li Q, Ng TW, Dodson KW, et al. The differential affinity of the usher for chaperone-subunit complexes is required for assembly of complete pili. Mol. Microbiol. 2010; 76: 159-172. doi: 10.1111/j.1365-2958.2010.07089.x
9. Starr T, Ng TW, Wehrly TD, Knodler LA, Celli J. Brucella intracellular replication requires trafficking through the late endosomal/lysosomal compartment. Traffic. 2008; 9: 678-694. doi: 10.1111/j.1600-0854.2008.00718.x
10. Ng TW, Akman L, Osisami M, Thanassi DG. The usher N-terminus is the initial targeting site for chaperone-subunit complexes and participates in subsequent pilus biogenesis events. J. Bacteriol. 2004; 186: 5321-5331. doi: 10.1128/JB.186.16.5321-5331.2004